Skip to main content
SpringerLink
Log in

Risk of SJS with artemether/lumefantrine for malaria

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Grundmark B, et al. Artemether/Lumefantrine and Stevens-Johnson syndrome: a recommendation for continued vigilance in malaria-endemic areas. WHO Pharmaceuticals Newsletter : 14-16, No. 2, 2018. Available from: URL: http://apps.who.int/iris/bitstream/handle/10665/272398/WPN-2018-02-eng.pdf?ua=1.

  2. Novartis. Response from Novartis (re Artemether/Lumefantrine and Stevens-Johnson syndrome: a recommendation for continued vigilance in malaria-endemic areas). WHO Pharmaceuticals Newsletter : 16-19, No. 2, Apr 2018. Available from: URL: http://apps.who.int/iris/bitstream/handle/10665/272398/WPN-2018-02-eng.pdf?ua=1.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of SJS with artemether/lumefantrine for malaria. Reactions Weekly 1701, 6 (2018). https://doi.org/10.1007/s40278-018-45838-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-45838-8

Search

Navigation